Apolipoprotein A4 Gene (APOA4) (Chromosome 11/Haplotypes/Intron Loss/Coronary Artery Disease/Apoal-APOC3 Deficiency) Sotirios K

Total Page:16

File Type:pdf, Size:1020Kb

Apolipoprotein A4 Gene (APOA4) (Chromosome 11/Haplotypes/Intron Loss/Coronary Artery Disease/Apoal-APOC3 Deficiency) Sotirios K Proc. Natl. Acad. Sci. USA Vol. 83, pp. 8457-8461, November 1986 Biochemistry Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4) (chromosome 11/haplotypes/intron loss/coronary artery disease/APOAl-APOC3 deficiency) SOTIRios K. KARATHANASIS*t, PETER OETTGEN*t, ISSAM A. HADDAD*t, AND STYLIANOS E. ANTONARAKISt *Laboratory of Molecular and Cellular Cardiology, Department of Cardiology, Children's Hospital and tDepartment of Pediatrics, Harvard Medical School, Boston, MA 02115; and tDepartment of Pediatrics, Genetics Unit, The Johns Hopkins University, School of Medicine, Baltimore, MD 21205 Communicated by Donald S. Fredrickson, July 11, 1986 ABSTRACT The genes coding for three proteins of the APOC3 deficiency and premature coronary artery disease plasma lipid transport system-apolipoproteins Al (APOAI), (13-15), hypertriglyceridemia (16), and hypoalphalipopro- C3 (APOC3), and A4 (APOA4)-are closely linked and teinemia (17). tandemly organized on the long arm ofhuman chromosome 11. In this report the nucleotide sequence of the human In this study the human APOA4 gene has been isolated and APOA4 gene has been determined. The results suggest that characterized. In contrast to APOAl and APOC3 genes, which the APOAI, APOC3, and APOA4 genes were derived from a contain three introns, the APOA4 gene contains only two. An common evolutionary ancestor and indicate that during intron interrupting the 5' noncoding region of the APOA1 and evolution the APOA4 gene lost one of its ancestral introns. APOC3 mRNAs is absent from the corresponding position of Screening of the APOA4 gene region for polymorphisms the APOA4 mRNA. However, similar to APOAI and APOC3 showed that two different Xba I restriction endonuclease genes, the introns of the APOA4 gene separate nucleotide sites are polymorphic in Mediterranean and Northern Euro- sequences coding for the signal peptide and the amphipathic pean populations. Haplotype analysis indicated that these domains in APOA4. These results suggest that the APOAI, polymorphisms do not display significant nonrandom asso- APOC3, and APOA4 genes were derived from a common ciation. Finally, restriction mapping of the APOA4 gene evolutionary ancestor and indicate that during evolution the region in a patient with combined APOA1-APOC3 deficiency APOA4 gene lost one of its ancestral introns. Two restriction and premature coronary artery disease indicated that this endonuclease sites, an Xba I located in the second intron of the patient has a structurally normal APOA4 gene. APOA4 gene and a different Xba I located 9 kilobases 3' to the APOA4 gene, are polymorphic in Mediterranean and Northern MATERIALS AND METHODS European populations. Haplotype analysis indicated that even Nucleotide Sequencing Determinations. DNA sequencing though these polymorphic sites are located within 9 kilobases was carried out either by the base-specific chemical cleavage they do not display significant nonrandom association. Finally, method (18) or by subcloning various DNA fragments in M13 restriction mapping analysis of DNA from a patient with vectors (19) and using the resulting single-stranded DNA combined APOAI-APOC3 deficiency and premature coronary templates for nucleotide sequence determination by the artery disease indicated that this patient has a structurally dideoxy chain-termination method (20). normal APOA4 gene. Isolation of DNA Fragments and Radioactive Labeling of Hybridization Probes. Cloned DNA fragments were isolated Apolipoproteins are lipid-binding proteins involved in the by electrophoresis in low-melting (Bio-Rad) agarose gels and transport of triglycerides, phospholipids, and cholesterol in purified by phenol extraction and ethanol precipitation. the plasma. Association ofapolipoproteins with lipids results These fragments were labeled using [a-32P]dCTP (Amer- in formation of lipid-protein particles (lipoproteins), the sham, 3000 Ci/mmol; 1 Ci = 37 GBq) as detailed (21). major carriers of lipids in the intra- and extravascular space. S1 Nuclease Mapping and Primer-Extension. Purified re- Apolipoprotein A4 (APOA4) is synthesized primarily in the striction DNA fragments were treated with bacterial alkaline intestine (1, 2) and represents a major protein constituent of phosphatase according to the specifications of the vendor newly secreted intestinal triglyceride-rich lipoproteins (IBI), extracted with phenol, precipitated with ethanol, and (chylomicrons) (3). The significant increase in APOA4 syn- 5' end labeled with [y-32P]ATP (Amersham, 3000 Ci/mmol) thesis and secretion by the intestine during fat absorption (4) using polynucleotide kinase (New England Biolabs). These 5' and the rapid dissociation of this protein from the surface of end-labeled fragments were used for S1 nuclease mapping lymph chylomicrons during catabolism of these particles (5, (22) and primer-extension analysis (23). 6) suggest that APOA4 plays a significant role in triglyceride Genomic Restriction Mapping Analysis and Statistical Meth- metabolism. Similarly, the possible involvement of APOA4 ods. Chromosomal DNA was prepared from peripheral blood in activation of lecithin-cholesterol acyltransferase [(LCAT) of normal [with regard to coronary artery disease (17)] phosphatidylcholine-sterol acyltransferase; EC 2.3.1.43] (7) individuals digested with restriction enzymes (New England and the influence of the LCAT reaction on the distribution of Biolabs), electrophoresed in 1% agarose gels, transferred onto APOA4 among different lipoproteins (8) may indicate that nitrocellulose filters (24), and hybridized with 32P-labeled DNA APOA4 is also involved in cholesterol metabolism. probes. These filters were washed and used for autoradiog- The genes coding for apolipoproteins Al (APOAJ), C3 raphy. Estimation of the nucleotide diversity (ir), heterozy- (APOC3), and A4 (APOA4) are closely linked and tandemly gosity (h), standardized nonrandom association (A), recombi- organized in the long arm of the human chromosome 11 nation frequency per kilobase (kb) ((D), and polymorphic infor- (9-12). Several different DNA polymorphisms in this region mation content (PIC value) was as described (25-28). of the human genome are associated with combined APOA1- Abbreviations: PIC, polymorphic information content; APO-, apo- The publication costs of this article were defrayed in part by page charge lipoprotein; kb, kilobase(s); bp, base pair(s); nt, nucleotide(s); payment. This article must therefore be hereby marked "advertisement" LCAT, lecithin-cholesterol acyltransferase; IVS, intervening se- in accordance with 18 U.S.C. §1734 solely to indicate this fact. quence; df, degree(s) of freedom. 8457 Downloaded by guest on September 25, 2021 8458 Biochemistry: Karathanasis et al. Proc. Natl. Acad. Sci. USA 83 (1986) APOA 1 APOC3 APOA4 3' 2). The start site (cap site) of this gene was determined by S1 513'iS'5pJ3' nuclease mapping analysis of K KH3 SR B R K RSKR H3 H3 8 adult human intestine total | 1Kbp e_ RNA using as probe a 468-bp Msp I DNA fragment extending between nucleotides (nt) -334 and 134 (Fig. 2). In addition, - AATAAA primer-extension analysis of this RNA was carried out by X P R P KAP - P P BPASmSe BX PSTSRSP - - using as primer a 91-bp I II 100bp ]- IY .. HIS_ BamHI-Msp DNA fragment I I 1 /-77'I f _-- I extending between nt 45 and 134 (Fig. 2). The resulting liV1/ IVS-2 k I// -- autoradiogram (Fig. 3) shows that S1 nuclease mapping (lane III I10b APO -5CAP -/ Poy-A 3' MRNA I' S) and primer-extension analysis (lane P) result in a 134-nt AUG UGA product. These data indicate that the start site of the human X P PHTSmH P88H P RHBHX P KP H PSTSRSPH HP || A APOA4 gene is located 54 residues 3' to the last nucleotide of IV lOObP 'i Y'(( r the TATA box (TTTAAAT) in this gene (Fig. 2). DNA Polymorphisms and Nucleotide Diversity of theAPOA4 Gene Region. Two DNA fragments containing APOA4 gene sequences, a 724-bp BamHI fragment extending between nt FIG. 1. (1) Restriction map of the human APOAJ, APOC3, and 39 and 763 (-probe I) and 1812-bp Sac I fragment extending APOA4 genes (open boxes). (H) Restriction map of the human between nt -3 and 1809 (probe II), were used as probes for APOA4 gene. "TATA box" and poly(A) signal are boxed. Introns restriction site polymorphism screening of Mediterranean [intervening sequence (IVS)] and exons (filled boxes) are indicated. and Northern European populations (Fig. 4). Of the total 27 (III) Structure of the APOA4 mRNA. The 5' (5' CAP) and 3' (Poly-A sites screened, only 2, an Xba I (XbaIA) 3') ends and initiation (AUG) and termination (UGA) codons are located in the IVS2 indicated. (IV) Direction and extent of nucleotide sequencing deter- of the APOA4 gene and a different Xba I (XbaIB) located 9 minations are shown by arrows below a map of the human APOA4 kb 3' to XbaIA, are polymorphic in both of these populations gene; bars on the left side of the maps indicate the nucleotide scale. (Table 1). The sizes of hybridization fragments obtained with Restriction enzymes are shown as B, BamHI; S, Sac I; R, EcoRI; each of the nonpolymorphic sites (Table 1) are identical for H3, HindIII; K, Kpn I; P, Pst; X, Xba I; Sm, Sma; T, Taq I; A, Acc every DNA sample studied (data not shown). Thus, the I; and H, Hpa II. Kbp, kilobase pairs; bp, base pairs. observed polymorphisms are most likely due to base substi- tutions rather than large deletions or insertions. Assuming RESULTS that these base substitutions are selectively neutral it is possible to estimate the nucleotide diversity. (ir; refs. 25-27) Isolation and Characterization of the Human APOA4 Gene. over the Genomic clones with overlapping DNA inserts spanning the 38-kb DNA segment containing the human APOA4 human APOAI, APOC3, and APOA4 genes have been gene. The or values for the Mediterranean and Northern isolated and characterized (12). These clones were used to European populations are 0.0022 and 0.0020, respectively. construct a restriction endonuclease map of the human The combined data from both populations indicate a ir value APOA4 gene (Fig. 1). The nucleotide sequence of this gene of 0.0021.
Recommended publications
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • The Expression of the Human Apolipoprotein Genes and Their Regulation by Ppars
    CORE Metadata, citation and similar papers at core.ac.uk Provided by UEF Electronic Publications The expression of the human apolipoprotein genes and their regulation by PPARs Juuso Uski M.Sc. Thesis Biochemistry Department of Biosciences University of Kuopio June 2008 Abstract The expression of the human apolipoprotein genes and their regulation by PPARs. UNIVERSITY OF KUOPIO, the Faculty of Natural and Environmental Sciences, Curriculum of Biochemistry USKI Juuso Oskari Thesis for Master of Science degree Supervisors Prof. Carsten Carlberg, Ph.D. Merja Heinäniemi, Ph.D. June 2008 Keywords: nuclear receptors; peroxisome proliferator-activated receptor; PPAR response element; apolipoprotein; lipid metabolism; high density lipoprotein; low density lipoprotein. Lipids are any fat-soluble, naturally-occurring molecules and one of their main biological functions is energy storage. Lipoproteins carry hydrophobic lipids in the water and salt-based blood environment for processing and energy supply in liver and other organs. In this study, the genomic area around the apolipoprotein genes was scanned in silico for PPAR response elements (PPREs) using the in vitro data-based computer program. Several new putative REs were found in surroundings of multiple lipoprotein genes. The responsiveness of those apolipoprotein genes to the PPAR ligands GW501516, rosiglitazone and GW7647 in the HepG2, HEK293 and THP-1 cell lines were tested with real-time PCR. The APOA1, APOA2, APOB, APOD, APOE, APOF, APOL1, APOL3, APOL5 and APOL6 genes were found to be regulated by PPARs in direct or secondary manners. Those results provide new insights in the understanding of lipid metabolism and so many lifestyle diseases like atherosclerosis, type 2 diabetes, heart disease and stroke.
    [Show full text]
  • 1 CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on A
    Page 1 of 55 Diabetes CETP inhibition improves HDL function but leads to fatty liver and insulin resistance in CETP-expressing transgenic mice on a high-fat diet Lin Zhu1,2, Thao Luu2, Christopher H. Emfinger1,2, Bryan A Parks5, Jeanne Shi2,7, Elijah Trefts3, Fenghua Zeng4, Zsuzsanna Kuklenyik5, Raymond C. Harris4, David H. Wasserman3, Sergio Fazio6 and John M. Stafford1,2,3,* 1VA Tennessee Valley Healthcare System, 2Division of Diabetes, Endocrinology, & Metabolism, 3Department of Molecular Physiology and Biophysics, 4Devision of Nephrology and Hypertension, Vanderbilt University School of Medicine. 5Division of Laboratory Sciences, Centers for Disease Control and Prevention. 6The Center for Preventive Cardiology at the Knight Cardiovascular Institute, Oregon Health & Science University. 7Trinity College of Art and Science, Duke University. * Address correspondence and request for reprints to: John. M. Stafford, 7445D Medical Research Building IV, Nashville, TN 37232-0475, phone (615) 936-6113, fax (615) 936- 1667 Email: [email protected] Running Title: CETP inhibition and insulin resistance Word Count: 5439 Figures: 7 Tables: 1 1 Diabetes Publish Ahead of Print, published online September 13, 2018 Diabetes Page 2 of 55 Abstract In clinical trials inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels but doesn’t robustly improve cardiovascular outcomes. About 2/3 of trial participants were obese. Lower plasma CETP activity is associated with increased cardiovascular risk in human studies, and protective aspects of CETP have been observed in mice fed a high-fat diet (HFD) with regard to metabolic outcomes. To define if CETP inhibition has different effects depending on the presence of obesity, we performed short- term anacetrapib treatment in chow- and HFD-fed CETP-transgenic mice.
    [Show full text]
  • The Crucial Roles of Apolipoproteins E and C-III in Apob Lipoprotein Metabolism in Normolipidemia and Hypertriglyceridemia
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Harvard University - DASH The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Sacks, Frank M. 2015. “The Crucial Roles of Apolipoproteins E and C-III in apoB Lipoprotein Metabolism in Normolipidemia and Hypertriglyceridemia.” Current Opinion in Lipidology 26 (1) (February): 56–63. doi:10.1097/mol.0000000000000146. Published Version doi:10.1097/MOL.0000000000000146 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:30203554 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#OAP HHS Public Access Author manuscript Author Manuscript Author ManuscriptCurr Opin Author Manuscript Lipidol. Author Author Manuscript manuscript; available in PMC 2016 February 01. Published in final edited form as: Curr Opin Lipidol. 2015 February ; 26(1): 56–63. doi:10.1097/MOL.0000000000000146. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia Frank M. Sacks Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA Abstract Purpose of review—To describe the roles of apolipoprotein C-III (apoC-III) and apoE in VLDL and LDL metabolism Recent findings—ApoC-III can block clearance from the circulation of apolipoprotein B (apoB) lipoproteins, whereas apoE mediates their clearance.
    [Show full text]
  • Lrp1 Modulators
    Last updated on February 14, 2021 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Lrp1 Modulators Evidence Summary Lrp1 has a variety of essential functions, mediated by a diverse array of ligands. Therapeutics will need to target specific interactions. Neuroprotective Benefit: Lrp1-mediated interactions promote Aβ clearance, Aβ generation, tau propagation, brain glucose utilization, and brain lipid homeostasis. The therapeutic effect will depend on the interaction targeted. Aging and related health concerns: Lrp1 plays mixed roles in cardiovascular diseases and cancer, dependent on context. Lrp1 is dysregulated in metabolic disease, which may contribute to insulin resistance. Safety: Broad-spectrum Lrp1 modulators are untenable therapeutics due to the high potential for extensive side effects. Therapies that target a specific Lrp1-ligand interaction are expected to have a better therapeutic profile. 1 Last updated on February 14, 2021 Availability: Research use Dose: N/A Chemical formula: N/A S16 is in clinical trials MW: N/A Half life: N/A BBB: Angiopep is a peptide that facilitates BBB penetrance by interacting with Lrp1 Clinical trials: S16, an Lrp1 Observational studies: sLrp1 levels are agonist was tested in healthy altered in Alzheimer’s disease, volunteers (n=10) in a Phase 1 cardiovascular disease, and metabolic study.
    [Show full text]
  • Apoa4 Antibody Cat
    ApoA4 Antibody Cat. No.: 6269 Western blot analysis of ApoA4 in chicken small intestine tissue lysate with ApoA4 antibody at 1 μg/mL Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Chicken, Human ApoA4 antibody was raised against a 20 amino acid synthetic peptide near the carboxy terminus of chicken ApoA4. IMMUNOGEN: The immunogen is located within the last 50 amino acids of ApoA4. TESTED APPLICATIONS: ELISA, WB ApoA4 antibody can be used for detection of ApoA4 by Western blot at 1 μg/mL. APPLICATIONS: Antibody validated: Western Blot in chicken samples. All other applications and species not yet tested. POSITIVE CONTROL: 1) Chicken Small Intestine Lysate Properties PURIFICATION: ApoA4 Antibody is affinity chromatography purified via peptide column. CLONALITY: Polyclonal ISOTYPE: IgG September 24, 2021 1 https://www.prosci-inc.com/apoa4-antibody-6269.html CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: ApoA4 Antibody is supplied in PBS containing 0.02% sodium azide. CONCENTRATION: 1 mg/mL ApoA4 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one STORAGE CONDITIONS: year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: APOA4 ALTERNATE NAMES: ApoA4 Antibody: Apolipoprotein A-IV, Apolipoprotein A4, Apo-AIV ACCESSION NO.: NP_990269 PROTEIN GI NO.: 71773110 GENE ID: 337 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References ApoA4 Antibody: Apolipoprotein A4 (also known as ApoA-IV) is a plasma protein that is O- linked glycoprotein after proteolytic processing.
    [Show full text]
  • Convergence of Genes Implicated in Alzheimer's Disease on the Cerebral
    Neurochemistry International 50 (2007) 12–38 www.elsevier.com/locate/neuint Review Convergence of genes implicated in Alzheimer’s disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis C.J. Carter 176 Downs Road, Hastings, East Sussex TN34 2DZ, UK Received 5 April 2006; received in revised form 30 June 2006; accepted 11 July 2006 Available online 12 September 2006 Abstract Polymorphic genes associated with Alzheimer’s disease (see www.polygenicpathways.co.uk) delineate a clearly defined pathway related to cerebral and peripheral cholesterol and lipoprotein homoeostasis. They include all of the key components of a glia/neurone cholesterol shuttle including cholesterol binding lipoproteins APOA1, APOA4, APOC1, APOC2, APOC3, APOD, APOE and LPA, cholesterol transporters ABCA1, ABCA2, lipoprotein receptors LDLR, LRP1, LRP8 and VLDLR, and the cholesterol metabolising enzymes CYP46A1 and CH25H, whose oxysterol products activate the liver X receptor NR1H2 and are metabolised to esters by SOAT1. LIPA metabolises cholesterol esters, which are transported by the cholesteryl ester transport protein CETP. The transcription factor SREBF1 controls the expression of most enzymes of cholesterol synthesis. APP is involved in this shuttle as it metabolises cholesterol to 7-betahydroxycholesterol, a substrate of SOAT1 and HSD11B1, binds to APOE and is tethered to LRP1 via APPB1, APBB2 and APBB3 at the cytoplasmic domain and via LRPAP1 at the extracellular domain. APP cleavage products are also able to prevent cholesterol binding to APOE. BACE cleaves both APP and LRP1. Gamma-secretase (PSEN1, PSEN2, NCSTN) cleaves LRP1 and LRP8 as well as APP and their degradation products control transcription factor TFCP2, which regulates thymidylate synthase (TS) and GSK3B expression.
    [Show full text]
  • Apolipoprotein (Apo) A-IV Is a Protein Synthesized by the Small Intestine In
    UNIVERSITY OF CINCINNATI Date:___________________ I, _________________________________________________________, hereby submit this work as part of the requirements for the degree of: in: It is entitled: This work and its defense approved by: Chair: _______________________________ _______________________________ _______________________________ _______________________________ _______________________________ THE STRUCTURE AND FUNCTION OF APOLIPOPROTEIN A-IV By Kevin Joseph Pearson B.S., University of Pittsburgh, 1999 May 2005 A dissertation presented to the faculty of the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Pathobiology and Molecular Medicine Committee Members W. Sean Davidson-Chair Patrick Tso Ronald J. Jandacek Min Liu Simon L. Newman Randall R. Sakai THESIS ABSTRACT Apolipoprotein (apo) A-IV is a protein synthesized by the small intestine in response to lipid absorption. It has been proposed to play a role in cholesterol efflux, lipoprotein metabolism and food intake. Unfortunately, little information on its structure/function relationship is known. Therefore, it was important to establish a recombinant expression system for apoA-IV so deletion mutagenesis could be performed to achieve the specific aims. The following aims address the hypothesis that specific regions of apoA-IV are involved in its ability to interact with lipid and inhibit food intake. Aim 1: Determine the region of apoA-IV that is responsible for its ability to bind lipid as well as to identify the generalities of its structure. Initially, it was found that removing the C-terminal 44 amino acids from human apoA-IV caused a significant increase in lipid binding ability as compared to WT. Eventually, a smaller region from amino acid 333-343 was established as the ‘inhibitory’ region of apoA-IV at the C- terminus.
    [Show full text]
  • MUSCLE'go'terms
    MUSCLE'GO'Terms AtgΔ/Δ;Fed AtgΔ/Δ;Fed Atg7flox/flox;Fed/AtgΔ/Δ;Fed Upregulated Downregulated Comparison Genes AtgΔ/Δ;Fed Upregulated Genes Genes AtgΔ/Δ;Fed Downregulated Genes p-value Bonferroni GO:0060537 muscle tissue development 3 TIPARP, FOXP1, CSRP3 -9 MEF2C, TNNT2, RXRG, MYOG, PAK1, RARB, CHRNA1, TPM1, TGFB2 3.03E-06 0.00445 GO:0014706 striated muscle tissue development 2 FOXP1, CSRP3 -9 MEF2C, TNNT2, RXRG, MYOG, PAK1, RARB, CHRNA1, TPM1, TGFB2 1.09E-05 0.015959 AtgΔ/Δ;Fasted AtgΔ/Δ;Fasted Atg7Δ/Δ;Fed/AtgΔ/Δ;Fasted Upregulated Downregulated Comparison Genes AtgΔ/Δ;Fasted Upregulated Genes Genes AtgΔ/Δ;Fasted Downregulated Genes p-value Bonferroni CXCL13, MBL2, ORM1, FGB, PLG, CFI, F2, KNG1, FGG, SAA2, FGA, CRP, HC, ARG1, C4BP, SERPINA3N, F9, C8A, AHSG, APOH, ORM2, SERPINA1A, SAA1, SAA4, F13B, SERPINC1, F5, SERPINA1B, C9, CXCL1, SERPINF2, GO:0009611 PROC, F12, KLKB1, SLC7A2, MBL1, SERPIND1, ORM3, SAA3, C8B, CD14, response to wounding 52 F7, MST1, C8G, C2, CXCL10, PPARA, F10, CXCL2, CHI3L3, C3, KLF6 -4 CCL21A, CCL8, PF4, EFEMP2 1.70E-20 3.73E-17 MBL1, MBL2, C9, C3, CRP, AHSG, SERPINA1B, SAA2, SAA1, SERPINA1A, GO:0002526 C2, CFI, HC, SAA3, SAA4, C8G, C8A, ORM1, C8B, SERPINA3N, C4BP, acute inflammatory response 26 SLC7A2, SERPINF2, F2, ORM2, ORM3 0 5.78E-17 2.43E-13 EGLN3, UOX, MOSC1, CYP2E1, HGD, HPD, CYP2D26, CYP2C68, CYP2C70, CYP3A25, PAH, TDO2, RDH7, CYP7B1, CYP2D10, AASS, CYP3A13, CYP2B10, CYP8B1, H6PD, CYP2C29, CYP1A2, CYP2C37, F5, CYP2C50, CYP17A1, CYP2A4, BC089597, CYP3A11, CYP2A12, CYP2F2, CDO1, HSD17B2, DPYD, ALDH8A1, CYP4A10,
    [Show full text]
  • Apolipoprotein B: a Risk-Enhancing Factor in the Primary Prevention of Cardiovascular Disease
    Apolipoprotein B: a Risk-enhancing Factor in the Primary Prevention of Cardiovascular Disease The American College of Cardiologists and the American Heart • elevated high-sensitivity C-reactive Protein (≥ 2.0 mg/L); Association recently issued an updated guideline to help address • elevated Lipoprotein(a) – ≥ 50 mg/dL constitutes risk-enhancing the primary prevention of cardiovascular disease at population and factor; relative indication for measurement is family history of individual patient levels. This 2019 guideline combines existing premature ASCVD; scientific statements, expert consensus, and clinical practice guidelines • elevated Apolipoprotein B (≥ 130 mg/dL constitutes risk- and adds new recommendations for physical activity, aspirin use, enhancing factor; relative indication for measurement is and tobacco use. Suggestions for team-based care, shared decision triglyceride ≥ 200 mg/dL (≥ 130 mg/dL corresponds to LDL-C > making, and assessment of social determinants of health round out a 160 mg/dL). comprehensive but focused approach to primary prevention.1 The role of low-density lipoprotein (LDL) particles has been To enhance clinician-patient discussions and help inform prevention documented to elevate patient risk for ASCVD and is well known in strategies, the guideline advocates, among other things, estimating the development and progression of ASCVD.3 As stated in the Journal an individual’s 10-year risk for atherosclerotic cardiovascular disease of Family Medicine, LDL particles move into the arterial wall via a (ASCVD) to1: gradient-driven process. Once inside the intima, LDL particles that bind to the arterial wall are oxidized and subsequently taken up by • match the intensity of interventions with patient’s risk, macrophages to form foam cells.3 The greater the circulating levels • maximize the expected benefit, and of LDL over time, the greater the acceleration of this process and the • minimize possible harm from overtreatment.
    [Show full text]
  • Apolipoprotein and LRP1-Based Peptides As New Therapeutic Tools in Atherosclerosis
    Journal of Clinical Medicine Review Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis Aleyda Benitez Amaro 1,2, Angels Solanelles Curco 2, Eduardo Garcia 1,2, Josep Julve 3,4 , Jose Rives 5,6, Sonia Benitez 7,* and Vicenta Llorente Cortes 1,2,8,* 1 Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), 08036 Barcelona, Spain; [email protected] (A.B.A.); [email protected] (E.G.) 2 Biomedical Research Institute Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain; [email protected] 3 Metabolic Basis of Cardiovascular Risk Group, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain; [email protected] 4 CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain 5 Biochemistry Department, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain; [email protected] 6 Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, 08016 Barcelona, Spain 7 Cardiovascular Biochemistry Group, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08041 Barcelona, Spain 8 CIBERCV, Institute of Health Carlos III, 28029 Madrid, Spain * Correspondence: [email protected] (S.B.); [email protected] or [email protected] (V.L.C.) Abstract: Apolipoprotein (Apo)-based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC-II and ApoE mimetics exert anti-atherosclerotic effects by improving lipid profile. ApoC-II mimetics reverse hypertriglyceridemia and ApoE-based peptides such as Ac-hE18A-NH2 Citation: Benitez Amaro, A.; reduce cholesterol and triglyceride (TG) levels in humans.
    [Show full text]
  • Apolipoprotein A-IV: a Multifunctional Protein Involved in Protection Against Atherosclerosis and Diabetes
    cells Review Apolipoprotein A-IV: A Multifunctional Protein Involved in Protection against Atherosclerosis and Diabetes Jie Qu 1, Chih-Wei Ko 1, Patrick Tso 1 and Aditi Bhargava 2,* 1 Department of Pathology and Laboratory Medicine, Metabolic Diseases Institute, University of Cincinnati, 2180 E Galbraith Road, Cincinnati, OH 45237-0507, USA; [email protected] (J.Q.); [email protected] (C.-W.K.); [email protected] (P.T.) 2 Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, 513 Parnassus Avenue, San Francisco, CA 94143-0556, USA * Correspondence: [email protected]; Tel.: +1-415-502-8453 Received: 9 March 2019; Accepted: 2 April 2019; Published: 5 April 2019 Abstract: Apolipoprotein A-IV (apoA-IV) is a lipid-binding protein, which is primarily synthesized in the small intestine, packaged into chylomicrons, and secreted into intestinal lymph during fat absorption. In the circulation, apoA-IV is present on chylomicron remnants, high-density lipoproteins, and also in lipid-free form. ApoA-IV is involved in a myriad of physiological processes such as lipid absorption and metabolism, anti-atherosclerosis, platelet aggregation and thrombosis, glucose homeostasis, and food intake. ApoA-IV deficiency is associated with atherosclerosis and diabetes, which renders it as a potential therapeutic target for treatment of these diseases. While much has been learned about the physiological functions of apoA-IV using rodent models, the action of apoA-IV at the cellular and molecular levels is less understood, let alone apoA-IV-interacting partners. In this review, we will summarize the findings on the molecular function of apoA-IV and apoA-IV-interacting proteins.
    [Show full text]